The potential role of neuroinflammation and transcription factors in Parkinson disease

Dialogues in Clinical Neuroscience

Volumn 19, Issue 1, 2017, Pages 71-80

  Tiwari, Prafulla Chandra ^a   Pal, Rishi ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Apoptosis; Autophagy; Neuroinflammation; Parkinson disease; Signaling pathway; Transcription factor

Indexed keywords

BINDING PROTEIN; CHEMOKINE; CYTOKINE; FAS ASSOCIATED FACTOR 1; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTOR YY1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; DOPAMINE;

ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HUMAN; MACROPHAGE ACTIVATION; MICROGLIA; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; WNT SIGNALING PATHWAY; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; PATHOPHYSIOLOGY; DISEASE EXACERBATION; PROTEIN FUNCTION; VULNERABILITY; WNT SIGNALING;

HUMANS; INFLAMMATION; NEUROIMMUNOMODULATION; PARKINSON DISEASE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85020397965     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Gautam RK, Tiwari PC, Mansoori AN, Biswas T, Gupta MM. Parkinson's disease-a molecular approach. J Pharm Res. 2012;5(11):5188-5193
2. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005;28:57-87
3. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1-14
4. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318
5. Causes of Parkinson's disease. Module 3 of Parkinson Medications online course. ATrain Education website. Available at: https://www.atrainceu. com/course-module/1874200-080_antiparkinson-strategies-module-03. Accessed 08 January 2017. Copyright © ATrain Education Inc
6. Bonifati V, Rizzu P, Squitieri F, et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24(3):159-160
7. Schapira AH. Mitochondrial disease. Lancet. 2006;368(9529):70-82
8. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989;1(8649):1269
9. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol. 2003;91:133-142
10. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158-1160
11. Zeng KW, Zhao MB, Ma ZZ, Jiang Y, Tu PF. Protosappanin A inhibits oxidative and nitrative stress via interfering the interaction of transmembrane protein CD14 with Toll-like receptor-4 in lipopolysaccharideinduced BV-2 microglia. Int Immunopharmacol. 2012;14(4):558-569
12. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience. 2012;211:51-76
13. Barcia C. Glial-mediated inflammation underlying parkinsonism. Scientifica (Cairo). 2013;2013:357805
14. Jung CH, Seo M, Otto NM, Kim DH. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. Autophagy. 2011;7(10):1212-1221
15. Kanaan NM, Kordower JH, Collier TJ. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging. 2010;31(6):937-952
16. Liu M, Bing G. Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011;2011:327089
17. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord. 2011;26(1):6-17
18. Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience. 2015;302:89-102
19. Chao Y, Wong SC, Tan EK. Evidence of inflammatory system involvement in Parkinson's disease. Biomed Res Int. 2014;2014:308654
20. Iannaccone S, Cerami C, Alessio M, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord. 2013;19(1):47-52
21. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57(2):168-175
22. Gillardon F, Schmid R, Draheim H. Parkinson's disease-linked leucinerich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience. 2012;208:41-48
23. Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32(5):1602-1611
24. Harms AS, Cao S, Rowse AL, et al. MHCII is required for a-synucleininduced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013;33(23):9592-9600
25. Su X, Federoff HJ. Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. Biomed Res Int. 2014;2014:275178
26. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69
27. Tsoulfas G, Geller DA. NF-κB in transplantation: friend or foe? Transpl Infect Dis. 2001;3(4):212-219
28. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-κB. J Leukoc Biol. 1999;65(3):291-298
29. Roebuck KA. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res. 1999;19(5):429-438
30. Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651
31. Gauss KA, Nelson-Overton LK, Siemsen DW, Gao Y, DeLeo FR, Quinn MT. Role of NF-κB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-a. J Leukoc Biol. 2007;82(3):729-741
32. Chen CC, Manning AM. Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB. Agents Actions Suppl. 1995;47:135-141
33. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107(1):7-11
34. Lawrence T, Fong C. The resolution of inflammation: anti-inflammatory roles for NF-κB. Int J Biochem Cell Biol. 2010;42(4):519-523
35. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69
36. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential production of and migratory response to β chemokines by human microglia and astrocytes. J Infect Dis. 1997;175(2):478-481
37. Przanowski P, Dabrowski M, Ellert-Miklaszewska A, et al. The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J Mol Med (Berl). 2014;92(3):239-254
38. Tanaka S, Ishii A, Ohtaki H, Shioda S, Yoshida T, Numazawa S. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation. 2013;10:143
39. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511
40. Banerjee A, Gerondakis S. Coordinating TLR-activated signaling pathways in cells of the immune system. Immunol Cell Biol. 2007;85(6):420-424
41. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 2003;301(5633):640-643
42. Bhattacharyya S, Ratajczak CK, Vogt SK, et al. TAK1 targeting by glucocorticoids determines JNK and IB regulation in Toll-like receptor-stimulated macrophages. Blood. 2010;115(10):1921-1931
43. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for lateonset idiopathic Parkinson's disease. Ann Neurol. 2002;52(5):549-555
44. Betarbet R, Anderson LR, Gearing M, et al. Fas-associated factor 1 and Parkinson's disease. Neurobiol Dis. 2008;31(3):309-315
45. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403-417
46. Gaestel M. MAPKAP kinases-MKs-two's company, three's a crowd. Nat Rev Mol Cell Biol. 2006;7(2):120-130
47. Yang Y, Liu H, Yao X. Understanding the molecular basis of MK2-p38a signaling complex assembly: insights into protein-protein interaction by molecular dynamics and free energy studies. Mol Biosyst. 2012;8(8):2106-2118
48. Harper SJ, LoGrasso P. Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal. 2001;13(5):299-310
49. Choi SJ, Paek HJ, Yu J. Oxidative stress by layered double hydroxide nanoparticles via an SFK-JNK and p38-NF-κB signaling pathway mediates induction of interleukin-6 and interleukin-8 in human lung epithelial cells. Int J Nanomedicine. 2015;10:3217-3229
50. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol. 1999;1(2):94-97
51. Fyhrquist N, Matikainen S, Lauerma A. MK2 signaling: lessons on tissue specificity in modulation of inflammation. J Invest Dermatol. 2010;130(2):342-344
52. Neininger A, Kontoyiannis D, Kotlyarov A, et al. MK2 targets AUrich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem. 2002;277(5):3065-3068
53. Culbert AA, Skaper SD, Howlett DR, et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2006;281(33):23658-23667
54. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med. 1994;180(5):1587-1590
55. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immuol. 1998;16:137-161
56. Zhu Y, Yang GY, Ahlemeyer B, et al. Transforming growth factor-β1 increases bad phosphorylation and protects neurons against damage. J Neurosci. 2002;22(10):3898-3909
57. Prehn JH, Bindokas VP, Marcuccilli CJ, Krajewski S, Reed JC, Miller RJ. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci U S A. 1994;91(26):12599-12603
58. Wyss-Coray T, Borrow P, Brooker MJ, Mucke L. Astroglial overproduction of TGF-β1 enhances inflammatory central nervous system disease in transgenic mice. J Neuroimmunol. 1997;77(1):45-50
59. Unsicker K, Krieglstein K. Co-activation of TGF-ss and cytokine signaling pathways are required for neurotrophic functions. Cytokine Growth Factor Rev. 2000;11(1-2):97-102
60. Unsicker K, Krieglstein K. TGF-βs and their roles in the regulation of neuron survival. Adv Exp Med Biol. 2002;513:353-374
61. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochem Biophys Acta. 2010;1804(3):433-439
62. Takei N, Nawa H. mTOR signaling and its roles in normal and abnormal brain development. Front Mom Neurosci. 2014;7:28
63. Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 2009;21(6):827-835
64. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33(2):67-75
65. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(pt 20):3589-3594
66. Neufeld TP. TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol. 2010;22(2):157-168
67. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18(23):2893-2904
68. Canal M, Romani-Aumedes J, Martin-Flores N, Perez-Fernandez V, Malagelada C. RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front Cell Neurosci. 2014;8:313
69. Castelo-Branco G, Wagner J, Rodriguez FJ, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A. 2003;100(22):12747-12752
70. Andersson ER, Salto C, Villaescusa JC, et al. Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc Natl Acad Sci U S A. 2013;110(7): E602-E610
71. Parish CL, Castelo-Branco G, Rawal N, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest. 2008;118(1):149-160
72. Ohnuki T, Nakamura A, Okuyama S, Nakamura S. Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease. Brain Res. 2010; 1346:26-42
73. L'Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis. 2011;41(2):508-527
74. Gollamudi S, Johri A, Calingasan NY, Yang L, Elemento O, Beal MF. Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PloS One. 2012;7(5):e36191
75. Dun Y, Li G, Yang Y, et al. Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci Lett. 2012;525(2):83-88
76. Wei L, Sun C, Lei M, et al. Activation of Wnt/β-catenin pathway by exogenous Wnt1 protects SH-SY5Y cells against 6-hydroxydopamine toxicity. J Mol Neurosci. 2013;49(1):105-115
77. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19(5):378-387
78. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143-164
79. Ji KA, Yang MS, Jou I, Shong MH, Joe EH. Thrombin induces expression of cytokine-induced SH2 protein (CIS) in rat brain astrocytes: involvement of phospholipase A2, cyclooxygenase, and lipoxygenase. Glia. 2004;48(2):102-111
80. Yang MS, Lee J, Ji KA, et al. Thrombin induces suppressor of cytokine signaling 3 expression in brain microglia via protein kinase Cd activation. Biochim Biophys Res Commun. 2004;317(3):811-816
81. Kim JH, Choi DJ, Jeong HK, et al. DJ-1 facilitates the interaction between STAT1 and its phosphatase, SHP-1, in brain microglia and astrocytes: a novel anti-inflammatory function of DJ-1. Neurobiol Dis. 2013;60:1-10
82. He Y, Casaccia-Bonnefil P. The Yin and Yang of YY1 in the nervous system. J Neurochem. 2008;106(4):1493-1502
83. Yu YT, Breitbart RE, Smoot LB, Lee Y, Mahdavi V, Nadal-Ginard B. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Devel. 1992;6(9):1783-1798
84. Gong X, Tang X, Wiedmann M, et al. Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron. 2003;38(1):33-46
85. Smith PD, Mount MP, Shree R, et al. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci. 2006;26(2):440-447
86. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997;386(6622):296-299
87. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science. 1999;286(5440):785-790
88. Liu L, Cavanaugh JE, Wang Y, Sakagami H, Mao Z, Xia Z. ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNFpromoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci U S A. 2003;100(14):8532-8537
89. Wang X, She H, Mao Z. Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3 in neuronal apoptosis. J Biol Chem. 2009;284(47):32619-32626
90. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44(4):595-600
91. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607
92. Krejci P, Prochazkova J, Bryja V, Kozubik A, Wilcox WR. Molecular pathology of the fibroblast growth factor family. Hum Mutat. 2009;30(9):1245-1255
93. Murase S, McKay RD. A specific survival response in dopamine neurons at most risk in Parkinson's disease. J Neurosci. 2006;26(38):9750-9760
94. Ohmachi S, Mikami T, Konishi M, Miyake A, Itoh N. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res. 2003;72(4):436-443
95. Ohmachi S, Watanabe Y, Mikami T, et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochim Biophys Res Commun. 2000;277(2):355-360
96. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. a-Synuclein in Lewy bodies. Nature. 1997;388(6645):839-840
97. Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of a-synuclein. Am J Hum Genet. 2008;82(2):283-289
98. van der Walt JM, Noureddine MA, Kittappa R, et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet. 2004;74(6):1121-1127
99. Satake W, Mizuta I, Suzuki S, et al. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport. 2007;18(9):937-940